Leiter's Compounding Recalls Mitomycin Injection Due to Sterility Concerns
Leiter's Compounding is recalling Mitomycin 0.02% injections because the filters used to produce them were recalled, raising concerns about sterility.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II. According to the rubric, an FDA Class II recall involving a significant hazard such as lack of sterility in an injectable drug corresponds to a Severe (4) rating.
Plain-English summary
Leiter's Compounding, located in San Jose, California, is recalling Mitomycin 0.02% (0.2 mg/mL) in Sterile Water for Injection. The product is compounded in 1 mL total volume in a 2 mL vial and is preservative-free. The recall involves 76,315 total units distributed nationwide.
The recall is being conducted due to a lack of assurance of sterility. All compounded products within their expiration dates that were produced using the recalled filters are affected. The expiration dates for the affected lots range from 11/05/2016 to 12/10/2016.
Consumers and healthcare providers should stop using the recalled product and contact their pharmacist or the recalling firm for further instructions on disposal or replacement.
The recalled product
- Product
- Mitomycin 0.02% (0.2 mg/mL) in Sterile Water for Injection (Injection) 1 mL Total Volume in a 2 mL Vial (Preservative Free), Compounded by Leiter's Compounding, San Jose, CA --- NDC 70360-005-35
- Manufacturer
- Leiter's Compounding
- Category
- Drug — Compounded Injectable
- Affected units
- 76,315
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- All unexpired lots
- Expirations dates of .11/05/2016 to 12/10/2016.
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 9 recalled by Leiter's Compounding under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 9 products in this recall →Related recalls
Same manufacturer · Leiter's Compounding
See all →- SevereLeiter's Compounding Recalls Cefuroxime Sodium Injection Due to Sterility Concerns
FDA (Drugs) · 2016-10-19
- SevereLeiter's Compounding Recalls Moxifloxacin Intravitreal Injection Due to Sterility Concerns
FDA (Drugs) · 2016-10-19
- SevereFDA Recalls Lidocaine and Phenylephrine Injection Due to Sterility Concerns
FDA (Drugs) · 2016-10-19
- SevereLeiter's Compounding Recalls Vancomycin Injection Due to Sterility Concerns
FDA (Drugs) · 2016-10-19
- SevereLeiter's Compounding Recalls Atropine Sulfate Ophthalmic Solution Due to Sterility Concerns
FDA (Drugs) · 2016-10-19
Same hazard · sterility
See all →- SevereK.C. Pharmaceuticals Recalls Target Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tri-MIX Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Semaglutide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Leader Advanced Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
Similar recalls
- SevereMitomycin Injectable Recalled Due to Sterility Assurance Concerns
FDA (Drugs) · 2013-06-12
- HighMitomycin Injection Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2022-11-09
- SevereLeiter's Pharmacy Recalls Lidocaine/Phenylephrine Vials Due to Sterility Concerns
FDA (Drugs) · 2013-09-25
- SevereLeiter's Pharmacy Recalls Dextrose 50% Injection Vials Due to Sterility Concerns
FDA (Drugs) · 2013-09-25
- SevereMitomycin Injectable Vials Recalled for Sterility Assurance Concerns
FDA (Drugs) · 2014-11-12
- SevereLeiter's Pharmacy Recalls Hyaluronidase Vials Due to Sterility Concerns
FDA (Drugs) · 2013-09-25